Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19
Copyright © 2021 Massachusetts Medical Society..
BACKGROUND: Thrombosis and inflammation may contribute to the risk of death and complications among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation may improve outcomes in noncritically ill patients who are hospitalized with Covid-19.
METHODS: In this open-label, adaptive, multiplatform, controlled trial, we randomly assigned patients who were hospitalized with Covid-19 and who were not critically ill (which was defined as an absence of critical care-level organ support at enrollment) to receive pragmatically defined regimens of either therapeutic-dose anticoagulation with heparin or usual-care pharmacologic thromboprophylaxis. The primary outcome was organ support-free days, evaluated on an ordinal scale that combined in-hospital death (assigned a value of -1) and the number of days free of cardiovascular or respiratory organ support up to day 21 among patients who survived to hospital discharge. This outcome was evaluated with the use of a Bayesian statistical model for all patients and according to the baseline d-dimer level.
RESULTS: The trial was stopped when prespecified criteria for the superiority of therapeutic-dose anticoagulation were met. Among 2219 patients in the final analysis, the probability that therapeutic-dose anticoagulation increased organ support-free days as compared with usual-care thromboprophylaxis was 98.6% (adjusted odds ratio, 1.27; 95% credible interval, 1.03 to 1.58). The adjusted absolute between-group difference in survival until hospital discharge without organ support favoring therapeutic-dose anticoagulation was 4.0 percentage points (95% credible interval, 0.5 to 7.2). The final probability of the superiority of therapeutic-dose anticoagulation over usual-care thromboprophylaxis was 97.3% in the high d-dimer cohort, 92.9% in the low d-dimer cohort, and 97.3% in the unknown d-dimer cohort. Major bleeding occurred in 1.9% of the patients receiving therapeutic-dose anticoagulation and in 0.9% of those receiving thromboprophylaxis.
CONCLUSIONS: In noncritically ill patients with Covid-19, an initial strategy of therapeutic-dose anticoagulation with heparin increased the probability of survival to hospital discharge with reduced use of cardiovascular or respiratory organ support as compared with usual-care thromboprophylaxis. (ATTACC, ACTIV-4a, and REMAP-CAP ClinicalTrials.gov numbers, NCT04372589, NCT04505774, NCT04359277, and NCT02735707.).
| Errataetall: |
CommentIn: N Engl J Med. 2021 Nov 18;385(21):2013. - PMID 34788515 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:385 |
|---|---|
| Enthalten in: |
The New England journal of medicine - 385(2021), 9 vom: 26. Aug., Seite 790-802 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
9005-49-6 |
|---|
| Anmerkungen: |
Date Completed 03.09.2021 Date Revised 23.11.2023 published: Print-Electronic ClinicalTrials.gov: NCT04372589, NCT04505774, NCT04359277, NCT02735707 CommentIn: N Engl J Med. 2021 Nov 18;385(21):2013. - PMID 34788515 Citation Status MEDLINE |
|---|
| doi: |
10.1056/NEJMoa2105911 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM328961469 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM328961469 | ||
| 003 | DE-627 | ||
| 005 | 20231225204053.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1056/NEJMoa2105911 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1096.xml |
| 035 | |a (DE-627)NLM328961469 | ||
| 035 | |a (NLM)34351721 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a ATTACC Investigators |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.09.2021 | ||
| 500 | |a Date Revised 23.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT04372589, NCT04505774, NCT04359277, NCT02735707 | ||
| 500 | |a CommentIn: N Engl J Med. 2021 Nov 18;385(21):2013. - PMID 34788515 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Massachusetts Medical Society. | ||
| 520 | |a BACKGROUND: Thrombosis and inflammation may contribute to the risk of death and complications among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation may improve outcomes in noncritically ill patients who are hospitalized with Covid-19 | ||
| 520 | |a METHODS: In this open-label, adaptive, multiplatform, controlled trial, we randomly assigned patients who were hospitalized with Covid-19 and who were not critically ill (which was defined as an absence of critical care-level organ support at enrollment) to receive pragmatically defined regimens of either therapeutic-dose anticoagulation with heparin or usual-care pharmacologic thromboprophylaxis. The primary outcome was organ support-free days, evaluated on an ordinal scale that combined in-hospital death (assigned a value of -1) and the number of days free of cardiovascular or respiratory organ support up to day 21 among patients who survived to hospital discharge. This outcome was evaluated with the use of a Bayesian statistical model for all patients and according to the baseline d-dimer level | ||
| 520 | |a RESULTS: The trial was stopped when prespecified criteria for the superiority of therapeutic-dose anticoagulation were met. Among 2219 patients in the final analysis, the probability that therapeutic-dose anticoagulation increased organ support-free days as compared with usual-care thromboprophylaxis was 98.6% (adjusted odds ratio, 1.27; 95% credible interval, 1.03 to 1.58). The adjusted absolute between-group difference in survival until hospital discharge without organ support favoring therapeutic-dose anticoagulation was 4.0 percentage points (95% credible interval, 0.5 to 7.2). The final probability of the superiority of therapeutic-dose anticoagulation over usual-care thromboprophylaxis was 97.3% in the high d-dimer cohort, 92.9% in the low d-dimer cohort, and 97.3% in the unknown d-dimer cohort. Major bleeding occurred in 1.9% of the patients receiving therapeutic-dose anticoagulation and in 0.9% of those receiving thromboprophylaxis | ||
| 520 | |a CONCLUSIONS: In noncritically ill patients with Covid-19, an initial strategy of therapeutic-dose anticoagulation with heparin increased the probability of survival to hospital discharge with reduced use of cardiovascular or respiratory organ support as compared with usual-care thromboprophylaxis. (ATTACC, ACTIV-4a, and REMAP-CAP ClinicalTrials.gov numbers, NCT04372589, NCT04505774, NCT04359277, and NCT02735707.) | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Pragmatic Clinical Trial | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 650 | 7 | |a Heparin, Low-Molecular-Weight |2 NLM | |
| 650 | 7 | |a Heparin |2 NLM | |
| 650 | 7 | |a 9005-49-6 |2 NLM | |
| 700 | 0 | |a ACTIV-4a Investigators |e verfasserin |4 aut | |
| 700 | 0 | |a REMAP-CAP Investigators |e verfasserin |4 aut | |
| 700 | 1 | |a Lawler, Patrick R |e verfasserin |4 aut | |
| 700 | 1 | |a Goligher, Ewan C |e verfasserin |4 aut | |
| 700 | 1 | |a Berger, Jeffrey S |e verfasserin |4 aut | |
| 700 | 1 | |a Neal, Matthew D |e verfasserin |4 aut | |
| 700 | 1 | |a McVerry, Bryan J |e verfasserin |4 aut | |
| 700 | 1 | |a Nicolau, Jose C |e verfasserin |4 aut | |
| 700 | 1 | |a Gong, Michelle N |e verfasserin |4 aut | |
| 700 | 1 | |a Carrier, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Rosenson, Robert S |e verfasserin |4 aut | |
| 700 | 1 | |a Reynolds, Harmony R |e verfasserin |4 aut | |
| 700 | 1 | |a Turgeon, Alexis F |e verfasserin |4 aut | |
| 700 | 1 | |a Escobedo, Jorge |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, David T |e verfasserin |4 aut | |
| 700 | 1 | |a Bradbury, Charlotte A |e verfasserin |4 aut | |
| 700 | 1 | |a Houston, Brett L |e verfasserin |4 aut | |
| 700 | 1 | |a Kornblith, Lucy Z |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Anand |e verfasserin |4 aut | |
| 700 | 1 | |a Kahn, Susan R |e verfasserin |4 aut | |
| 700 | 1 | |a Cushman, Mary |e verfasserin |4 aut | |
| 700 | 1 | |a McQuilten, Zoe |e verfasserin |4 aut | |
| 700 | 1 | |a Slutsky, Arthur S |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Keri S |e verfasserin |4 aut | |
| 700 | 1 | |a Gordon, Anthony C |e verfasserin |4 aut | |
| 700 | 1 | |a Kirwan, Bridget-Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Brooks, Maria M |e verfasserin |4 aut | |
| 700 | 1 | |a Higgins, Alisa M |e verfasserin |4 aut | |
| 700 | 1 | |a Lewis, Roger J |e verfasserin |4 aut | |
| 700 | 1 | |a Lorenzi, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Berry, Scott M |e verfasserin |4 aut | |
| 700 | 1 | |a Berry, Lindsay R |e verfasserin |4 aut | |
| 700 | 1 | |a Aday, Aaron W |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Beidh, Farah |e verfasserin |4 aut | |
| 700 | 1 | |a Annane, Djillali |e verfasserin |4 aut | |
| 700 | 1 | |a Arabi, Yaseen M |e verfasserin |4 aut | |
| 700 | 1 | |a Aryal, Diptesh |e verfasserin |4 aut | |
| 700 | 1 | |a Baumann Kreuziger, Lisa |e verfasserin |4 aut | |
| 700 | 1 | |a Beane, Abi |e verfasserin |4 aut | |
| 700 | 1 | |a Bhimani, Zahra |e verfasserin |4 aut | |
| 700 | 1 | |a Bihari, Shailesh |e verfasserin |4 aut | |
| 700 | 1 | |a Billett, Henny H |e verfasserin |4 aut | |
| 700 | 1 | |a Bond, Lindsay |e verfasserin |4 aut | |
| 700 | 1 | |a Bonten, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Brunkhorst, Frank |e verfasserin |4 aut | |
| 700 | 1 | |a Buxton, Meredith |e verfasserin |4 aut | |
| 700 | 1 | |a Buzgau, Adrian |e verfasserin |4 aut | |
| 700 | 1 | |a Castellucci, Lana A |e verfasserin |4 aut | |
| 700 | 1 | |a Chekuri, Sweta |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Jen-Ting |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Allen C |e verfasserin |4 aut | |
| 700 | 1 | |a Chkhikvadze, Tamta |e verfasserin |4 aut | |
| 700 | 1 | |a Coiffard, Benjamin |e verfasserin |4 aut | |
| 700 | 1 | |a Costantini, Todd W |e verfasserin |4 aut | |
| 700 | 1 | |a de Brouwer, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Derde, Lennie P G |e verfasserin |4 aut | |
| 700 | 1 | |a Detry, Michelle A |e verfasserin |4 aut | |
| 700 | 1 | |a Duggal, Abhijit |e verfasserin |4 aut | |
| 700 | 1 | |a Džavík, Vladimír |e verfasserin |4 aut | |
| 700 | 1 | |a Effron, Mark B |e verfasserin |4 aut | |
| 700 | 1 | |a Estcourt, Lise J |e verfasserin |4 aut | |
| 700 | 1 | |a Everett, Brendan M |e verfasserin |4 aut | |
| 700 | 1 | |a Fergusson, Dean A |e verfasserin |4 aut | |
| 700 | 1 | |a Fitzgerald, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Fowler, Robert A |e verfasserin |4 aut | |
| 700 | 1 | |a Galanaud, Jean P |e verfasserin |4 aut | |
| 700 | 1 | |a Galen, Benjamin T |e verfasserin |4 aut | |
| 700 | 1 | |a Gandotra, Sheetal |e verfasserin |4 aut | |
| 700 | 1 | |a García-Madrona, Sebastian |e verfasserin |4 aut | |
| 700 | 1 | |a Girard, Timothy D |e verfasserin |4 aut | |
| 700 | 1 | |a Godoy, Lucas C |e verfasserin |4 aut | |
| 700 | 1 | |a Goodman, Andrew L |e verfasserin |4 aut | |
| 700 | 1 | |a Goossens, Herman |e verfasserin |4 aut | |
| 700 | 1 | |a Green, Cameron |e verfasserin |4 aut | |
| 700 | 1 | |a Greenstein, Yonatan Y |e verfasserin |4 aut | |
| 700 | 1 | |a Gross, Peter L |e verfasserin |4 aut | |
| 700 | 1 | |a Hamburg, Naomi M |e verfasserin |4 aut | |
| 700 | 1 | |a Haniffa, Rashan |e verfasserin |4 aut | |
| 700 | 1 | |a Hanna, George |e verfasserin |4 aut | |
| 700 | 1 | |a Hanna, Nicholas |e verfasserin |4 aut | |
| 700 | 1 | |a Hegde, Sheila M |e verfasserin |4 aut | |
| 700 | 1 | |a Hendrickson, Carolyn M |e verfasserin |4 aut | |
| 700 | 1 | |a Hite, R Duncan |e verfasserin |4 aut | |
| 700 | 1 | |a Hindenburg, Alexander A |e verfasserin |4 aut | |
| 700 | 1 | |a Hope, Aluko A |e verfasserin |4 aut | |
| 700 | 1 | |a Horowitz, James M |e verfasserin |4 aut | |
| 700 | 1 | |a Horvat, Christopher M |e verfasserin |4 aut | |
| 700 | 1 | |a Hudock, Kristin |e verfasserin |4 aut | |
| 700 | 1 | |a Hunt, Beverley J |e verfasserin |4 aut | |
| 700 | 1 | |a Husain, Mansoor |e verfasserin |4 aut | |
| 700 | 1 | |a Hyzy, Robert C |e verfasserin |4 aut | |
| 700 | 1 | |a Iyer, Vivek N |e verfasserin |4 aut | |
| 700 | 1 | |a Jacobson, Jeffrey R |e verfasserin |4 aut | |
| 700 | 1 | |a Jayakumar, Devachandran |e verfasserin |4 aut | |
| 700 | 1 | |a Keller, Norma M |e verfasserin |4 aut | |
| 700 | 1 | |a Khan, Akram |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Yuri |e verfasserin |4 aut | |
| 700 | 1 | |a Kindzelski, Andrei L |e verfasserin |4 aut | |
| 700 | 1 | |a King, Andrew J |e verfasserin |4 aut | |
| 700 | 0 | |a et al |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t The New England journal of medicine |d 1945 |g 385(2021), 9 vom: 26. Aug., Seite 790-802 |w (DE-627)NLM000008184 |x 1533-4406 |7 nnns |
| 773 | 1 | 8 | |g volume:385 |g year:2021 |g number:9 |g day:26 |g month:08 |g pages:790-802 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1056/NEJMoa2105911 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 385 |j 2021 |e 9 |b 26 |c 08 |h 790-802 | ||